Royalty Pharma EVP Marshall Urist sells $235,594 in shares
Published . Updated .
Royalty Pharma EVP Marshall Urist sells $235,594 in shares Investing.com
Directly affected
- RPRX Royalty Pharma
Named in this report.
Indirectly affected
- NAMS NEW AMSTERDAM PHARMA CO ORDINARY SHARES
GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Royalty Pharma EVP Marshall Urist sells $235,594 in shares Investing.com
Source: Investing.com
The price since 12 Oct 2026: NewAmsterdam Pharma Co N.V (NAMS) versus the S&P 500
Since the first closing price after “Royalty Pharma EVP Marshall Urist sells $235,594 in shares,” NewAmsterdam Pharma Co N.V (NAMS) is +1.34%. The S&P 500 fund (SPY) is -1.47% over the same days, a +2.80% difference versus the market.
| Company | When | Move | Status |
|---|---|---|---|
| Acadia Healthcare (ACHC) | that day | +2.84% | final price |
| Acadia Healthcare (ACHC) | the next day | +3.35% | final price |
| Acadia Healthcare (ACHC) | two days later | +8.27% | final price |
| Acadia Healthcare (ACHC) | three days later | +6.12% | final price |
| Acadia Healthcare (ACHC) | three days earlier | -0.07% | final price |
| Acadia Healthcare (ACHC) | five days earlier | -1.30% | final price |
| Ascendis Pharma A/S (ASND) | that day | -1.02% | final price |
| Ascendis Pharma A/S (ASND) | the next day | -2.62% | final price |
| Ascendis Pharma A/S (ASND) | two days later | -0.97% | final price |
| Ascendis Pharma A/S (ASND) | three days later | -1.16% | final price |
| Ascendis Pharma A/S (ASND) | three days earlier | -0.44% | final price |
| Ascendis Pharma A/S (ASND) | five days earlier | -0.53% | final price |
| aTYR PHARMA (ATYR) | that day | -12.47% | final price |
| aTYR PHARMA (ATYR) | the next day | -19.29% | final price |
| aTYR PHARMA (ATYR) | two days later | -26.67% | final price |
| aTYR PHARMA (ATYR) | three days later | -25.18% | final price |
| aTYR PHARMA (ATYR) | three days earlier | +12.07% | final price |
| aTYR PHARMA (ATYR) | five days earlier | +17.92% | final price |
| BridgeBio Pharma (BBIO) | that day | +0.61% | final price |
| BridgeBio Pharma (BBIO) | the next day | -3.14% | final price |
| BridgeBio Pharma (BBIO) | two days later | -0.63% | final price |
| BridgeBio Pharma (BBIO) | three days later | +2.72% | final price |
| BridgeBio Pharma (BBIO) | three days earlier | +1.76% | final price |
| BridgeBio Pharma (BBIO) | five days earlier | +1.21% | final price |
| GLD | that day | -0.63% | final price |
| GLD | the next day | -0.76% | final price |
| GLD | two days later | -2.24% | final price |
| GLD | three days later | -0.50% | final price |
| GLD | three days earlier | -2.27% | final price |
| GLD | five days earlier | -1.32% | final price |
Filings that name NewAmsterdam Pharma Co N.V (NAMS) around 12 Oct 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around NewAmsterdam Pharma Co N.V (NAMS)
Companies tied to this story
- NAMS NewAmsterdam Pharma Co N.V
For “Royalty Pharma EVP Marshall Urist sells $235,594 in shares,” NewAmsterdam Pharma Co N.V (NAMS) is linked, with no stored direction, medium confidence. Reason on file: GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- RPRX Royalty Pharma
In “Royalty Pharma EVP Marshall Urist sells $235,594 in shares,” Royalty Pharma (RPRX) is linked, with no stored direction, medium confidence. Reason on file: GA selected RPRX as a RELATED security because its canonical security name directly matches this event's themes: royalty, pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
For “Royalty Pharma EVP Marshall Urist sells $235,594 in shares,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Royalty Pharma EVP Marshall Urist sells $235,594 in shares,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Royalty Pharma EVP Marshall Urist sells $235,594 in shares,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Royalty Pharma EVP Marshall Urist sells $235,594 in shares,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “Royalty Pharma EVP Marshall Urist sells $235,594 in shares” reaches NewAmsterdam Pharma Co N.V (NAMS)
“Royalty Pharma EVP Marshall Urist sells $235,594 in shares” (12 Oct 2026) reaches NewAmsterdam Pharma Co N.V (NAMS) through this story.
The link for NewAmsterdam Pharma Co N.V (NAMS) is this: GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Royalty Pharma (RPRX) is here too. Its reason reads: GA selected RPRX as a RELATED security because its canonical security name directly matches this event's themes: royalty, pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the NewAmsterdam Pharma Co N.V (NAMS) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. NAMS traded between 19.58 and 25.10 across 20 sessions. The latest close on file is 20.49. RPRX traded between 56.43 and 61.31 across 6 sessions. The latest close on file is 60.29.
What the saved facts support for NewAmsterdam Pharma Co N.V (NAMS)
46 out of 100
“Royalty Pharma EVP Marshall Urist sells $235,594 in shares” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.